Congratulations to OBI/OTRADI graduate AbSci for starting off the new year with a $10 million funding round and more growth on the horizon!
Thank you for your support of
OBI & OTRADI over the past year!
From 2015 to 2019, OBI Client Companies have:
2019 OBI Client Company Wins
- Aronora has completed a first-in-human clinical trial of their unique FXI inhibitor.
- Aronora announced a $9M+ deal for drug royalties from their novel stroke, clots and heart disease products.
- Aronora was just awarded a new Fast Track Phase I/II SBIR grant from the NIH for $2.5 million to help support the phase 2 clinical trial of AB002 (E-WE thrombin).
- Aronora has started a phase 2 clinical trial of AB002, a novel recombinant antithrombotic and anti-inflammatory enzyme. This is their third product candidate, in addition to AB012 and AB023, that had passed phase one. Information on this trial is available here.
- Aronora was awarded an SBIR matching grant from Business Oregon at the end of 2019.
- Bates Medical Systems pitched at MedTech & Digital Health Demo Day, a pitch event to showcase promising medtech and digital health startups from outside the bay area. At this event, they attracted the attention of Willamette Valley Capital Principal Bill Byers.
- Bates Medical Systems pitched at TAO’s Ignite: Health in November.
- Caregiven pitched at the Elevating Impact Summit (https://www.pdx.edu/impactentrepreneurs/elevating-impact-2019) .
- Caregiven was offered an opportunity to pitch at Techfest NW.
- Michele Houke joined Caregiven in May to oversee marketing efforts coming from WebMd.
- Caregiven participated in the Onramp Healthcare conference in Green Bay, WI.
- Caregiven participated in a Women’s Startup Lab event in Silicon Valley.
- Caregiven was selected to participate in Silver Moonshots Accelerator that concluded with a Demo Day to 50+ investors in aging-tech nationwide.
- Caregiven pitched at MedTech & Digital Health Demo Day, a pitch event to showcase promising medtech and digital health startups from outside the bay area. At this event, they attracted the attention of Willamette Valley Capital Principal Bill Byers.
- Caregiven was invited to be part of the HITLab.
- Caregiven was nominated into the Founders Network and was sponsored to attend their annual retreat in the Bay Area.
- Caregiven presented to LP’s of Rogue Venture’s Rogue Women Fund.
- Caregiven was a finalist and pitched at Plug-n-Play’s Tokyo’s Insurtech program.
- Caregiven was a finalist at PitchOregon presented by TiE.
- Caregiven was selected to participate in the Global Insurance Accelerator. Check out the press release.
- CytoImage received a Phase 0 grant award of $100,000 from Business Oregon for their miniaturized imaging platform using nanoparticles to detect drug resistant cancer.
- Floragenex saw a 13% increase in sales in 2019.
- Floragenex tested and validated operational plans to improve:
- Efficiency of lab processing by 5%
- Lab throughput by 15%
- Reduce cost by 5%
- Health Technology Innovations was awarded a $99,825 Enhanced Phase 0 Grant for integrated cryogenic electron microscopy intelligence solution for large imaging datasets in life sciences.
- HTI’s CryoDiscovery™ alpha was released and is being tested at OHSU/PNCC’s Cryo-EM center.
- Hemex Health was invited to present at the RESI Conference during JP Morgan week in San Francisco.
- Hemex Health was awarded a $150,000 SBIR grant to design and automate an affordable microchip-electrophoresis for sickle cell disease using a test cartridge that can be used in Hemex Health’s portable, easy-to-use analysis equipment.
- Hemex Health was invited to Ghana to discuss therapy for sickle cell patients. They also toured Korle Bu Teaching Hospital, which has been working to institute sickle cell screening for all newborns.
- Hemex Health won a $45K Catalyzing Pediatric Innovation Grant from CTIP (Consortium for Technology & Innovation in Pediatrics). The Grant will fund a study in Ghana to determine if a large number of infants can be screened efficiently for sickle cell disease during the vaccination process. Hemex presented at the CTIP Symposium held in Los Angeles.
- Madorra completed their Human Factors Study with great results.
- Madorra was featured in the UCSF Rosenman Health Technology podcast.
- Madorra was awarded a $500K Phase IIB SBIR extension grant from the NSF.
- Madorra delivered their pilot study device. Fully tested and documented: Madorra has finished its first medical device!
- Motusi pitched at MedTech & Digital Health Demo Day, a pitch event to showcase promising medtech and digital health startups from outside the bay area.
- OmnEcoil performed initial imaging-only testing of the OmnEcoil device on 7 patients.
- OmnEcoil finalized device design and prototype manufacturing after their initial patient testing.
- OmnEcoil obtained a Business Oregon SBIR matching grant of $50,000
- OmnEcoil submitted a pending $1.5M NIH grant application to fund a clinical trial of the device (both prostate imaging and biopsy) in ~40 patients.
- ProMedix was awarded a $100,000 Enhanced Phase 0 Grant for their medical device to measure dehydration.
- ProMedix received an investment from Ideaship LLC, which is a patent equity firm, to further establish their patent portfolio.
- Refeyn was a winner of The Scientist Top 10 Innovations in 2019.
- Refeyn was a winner of R&D 100 Awards in 2019. Refeyn was recognized under the Analytical / Test category for its work on mass photometry.
- Refeyn was one of the winning technologies under the Enabling Technologies category of Royal Society of Chemistry in 2019.
- Rewire Neuroscience pitched at and won Founders Live PDX in September.
- Rewire Neuroscience pitched at Oregon Bioscience Association’s Company Pitch Showcase in October.
- Rewire Neuroscience pitched at TAO’s Ignite: Health in November.
- Rewire Neuroscience has been accepted into the NVIDIA Inception Program.
- Rewire Neuroscience was awarded a Phase I SBIR grant from NIH in September
- Rewire Neuroscience was awarded a SBIR matching grant from Business Oregon in December
- Rewire Neuroscience was awarded a Kiesow research grant from the Legacy Research Institute in March
- Rewire Neuroscience pitched at the Life Science Innovation NW “fast-pitch” competition in April
- Rewire Neuroscience pitched at the at TechFest NW’s PitchFest competition in April
- Sirona Dx expanded pharma/biotech client base from 10 to 33
- Sirona Dx launched the Immune Portrait TME panel, enabling comprehensive analysis of the tumor microenvironment at sub-cellular resolution
- Sirona Dx expanded capabilities with addition of secure server and document control room to meet requirements of pharma clients
- Sirona Dx expanded executive leadership team with key strategic hires including:
- James Rader, Chief Financial Officer
- Camille B. Troup, Ph.D. Chief Technology Officer
- Anup Madan, Ph.D. Chief Operating Officer
- Ken J. Pennline, Ph.D. (RED Consulting), Business Strategy Advisor
- Sonivate Medical has raised more than $2 million, according to a form filed this week with the U.S. Securities and Exchange Commission according to Elizabeth Hayes of the Portland Business Journal. Click here to see the full Portland Business Journal article.
- Sparrow Pharmaceuticals presented at the following events.
- Keiretsu Family Office Forum, 7 March in Seattle
- Angel Capital Expo, 8 March in Seattle
- Cascadia Venture Forum, 11 March in Vancouver BC
- Sparrow Pharmaceuticals was named the best seed-stage company at Cascadia Venture Forum.
- Sparrow Pharmaceuticals was awarded $100K Business Oregon Enhanced Phase 0 grant to support certain regulatory, IP, and drug supply management activities. Sparrow Pharmaceuticals was also selected as a podium presenter during Life Science Innovation NW.
- Sparrow Pharmaceuticals was awarded a $100,000 Enhanced Phase 0 Grant to develop new drugs that work in combination with corticosteroids while mitigating adverse effects.
- Sparrow Pharmaceuticals completed Keiretsu Forum due diligence and has now received initial investments from Keiretsu members.
- Sparrow Pharmaceuticals passed $1M capital attracted to support development of safer steroids.
- Sparrow Pharmaceuticals received an FDA agreement to conduct their next clinical trial as designed, they converted US provisional to PCT patent application, and have allowance of 101st composition of matter patent.
- Sparrow Pharmaceuticals pitched at Oregon Bioscience Association’s Company Pitch Fest and won.
- Sparrow Pharmaceuticals was granted their 102nd patent in 2019.
- Sparrow Pharmaceuticals received preliminary examination of the PCT application that found novelty, non-obviousness and utility.
- Sparrow Pharmaceuticals initiated Phase 2 development activities for their lead product SPI-62.
- StoneStable was awarded a $49,930 STTR grant for stabilization of influenza vaccine by silica-coating. The company will conduct additional experiments to demonstrate efficacy of silica-coated flu vaccines that are much more stable than existing means.
- SUTUREGARD Medical was chosen from many startups to participate in the Innovation Pitch Competition and JP Morgan/RESI in San Francisco January 8th.
- SUTUREGARD presented at the Med Tech Monday in Costa Mesa on January 28th.
- SUTUREGARD completed round 2 of Willamette Valley Capital’s pitch series.
- SUTUREGARD participated in a surgical trade show in Las Vegas on February 3rd.
- SUTUREGARD has completed their seed round. Kaiser Permanente has approved their device for a 3-month product trial and surgeons from multiple specialties will be involved in this clinical trial.
- SUTUREGARD in introducing another Class I product, the HEMIGARDTM.
- SUTUREGARD now has 4 patents and 7 pending patents including international submissions.
- SUTUREGARD has partnered with OPERATION SMILE, the most prestigious global plastic surgery organization serving the underprivileged peoples of the world.
- SUTUREGARD has partnered with 9 sales consultants, covering the sunbelt regions of the US and all have existing relationships and accounts in SUTUGARD’s target specialties (dermatology, Mohs, general surgery and plastics).
- WebMarkets has updated SUTUREGARD’s website and is working on optimizing their SEO. Check out their new website (www.suturegard.com) and store (www.suturegard.store).
- SUTUREGARD has finalized their supply chain. The SUTUREGARD ISR is manufactured by Molded Devices Inc in Tempe, AZ, and the HEMIGARD by MBK Adhesives in Chatsworth, CA. Both products are sterilized and packaged by DemeTECH in Miami Lakes, FL. SUTUREGARD has partnered with Preferred Depot in Tustin, CA for domestic order fulfillment.
- SUTUREGARD recently recently returned from MEDICA, the worlds’ largest MedTech exposition, held this November 18-21 in Dusseldorf Germany! Thank you to Business Oregon for the support!
- Veana Therapeutics pitched at PitchfestNW. Out of 137 companies that pitched, Veana Therapeutics made the top 10 list.
- Veana Therapeutics recently received FDA approval to conduct a first-in-human clinical trial of its lead product, VIMO-001, an oral capsule, in combination with HerceptinTM for HER2 positive breast cancer patients that have failed all previous curative therapies.
- Veana Therapeutics recently entered into a collaboration with The University of Washington and the Fred Hutchinson Cancer Research Center, Seattle WA to clinically evaluate its first-in-class lead product, Veana Immune Modulator (VIMO-001) in combination with HerceptinTM in patients with advanced HER-2+ breast cancer. This FDA-approved trial is now open for patient enrollment.
- VIR Biotechnology’s vaccine technology shows promise against malaria.
- Vir Bio was featured in Xconomy highlighting their approach to tackling infectious disease. Check out the article.
- Vir Bio went public. In October, Vir raised $142.9 million in gross proceeds from an initial public offering.
- Virogenomics BioDevelopment was awarded a $99,173 SBIR Phase II Matching Grant to work on protein therapeutic treatments for multiple sclerosis, stroke and meth addiction.
- Virogenomics BioDevelopment was awarded a phase 1 sttr in March DRα1-MOG as a Next-Generation Immunotherapy for Methamphetamine Use Disorder”, collaborating with Jennifer Loftis and Marilyn Huckans, at OHSU & the VA. $300k
- Virogenomics BioDevelopment was awarded a phase I SBIR in September, “Developing novel fibrillin biomarkers for aortic disease”, collaborating with Lynn Sakai, OHSU & Shriner’s Children’s Hospital. $268k
- Virogenomics BioDevelopment applied for and was accepted into the NIH Commercialization Accelerator Program (CAP) program, as part of our ongoing Phase II STTR work for “Development of DRα1-MOG-35-55 for treatment of DR2 negative MS subjects”. The NIH CAP program provides mentoring and consultants to advise and help overcome hurdles to commercialization.
OBI WELCOMED ELEVEN
NEW STARTUPS TO OUR INCUBATOR IN 2019
Click here to learn more about our new companies.
Upcoming Events
OBI EVENT:
Lunch & Learn
The Space Race: Find and Equip Lab Space Quickly and Cost Effectively
February 20, 2020
February 20, 2020
12:00-1:00 PM
TAO EVENT: PDX Lunch & Learn – The Ultimate Guide to Communication & Management Across Generations
February 12, 2020
11:30 AM – 1:00 PM
Details Here
OEN EVENT: PubTalk – Picking the Right Incubator, Accelerator, or Co-Working Space
February 12, 2020
5:15 – 7:00 PM
Details Here
February 12, 2020
5:15 – 7:00 PM
Details Here
BIOCOM EVENT: Biocom’s Global Life Science Partnering Conference
February 25-27, 2020
San Diego, CA
Details Here
OEN & OTBC EVENT: Workshop – Startup 411 – How to Start Your Startup
March 5, 2020
11:30 AM – 2:30 PM
Details Here
Applications NOW OPEN for
Springboard Enterprises’ 2020 Health Innovation Hub: Life Sciences
Springboard is now recruiting women-led life science and healthcare companies seeking growth funding and connections to experts and strategic partners for product development and expansion. Areas of focus for the program include (but are not limited to) drugs, therapeutics, diagnostics, medtech, and medical devices.
The 2020 Health Hub programming has a special focus on women’s health innovation. Applications will be open through February 19th-24th (priority deadline February 19).